China's Pharma Leader Hengrui Enters IVD Sector with New Biotech Venture

Recently，Shanghai Ruiliyuan Biotechnology Co., Ltd. officially established, with Hu Hongcheng as the legal representative, and a registered capitalRMB 10 million.

The company is wholly owned by Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd., and the chairman of Hengrui Yuanzheng is Sun Piaoyang, the founder of Hengrui Pharma.

The business scope of this new company covers the development of human gene diagnosis and treatment technologies, the development and application of stem cell technologies, and the operation of Class III medical devices, among others. This also means that,Hengrui Pharma is accelerating its expansion into the medical device field, particularly in the IVD细分赛道.

Hengrui Pharma (Stock Code: 600276.SH, 01276.HK) was founded in 1970 and listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange in 2000 and 2025 respectively, becoming an “A+H” dual-listed company. As an innovative international pharmaceutical enterprise dedicated to the research, production, and promotion of high-quality drugs, Hengrui Pharma has, over its more than fifty years of development, consistently adhered to its original mission of being "patient-centered." Focusing on areas such as oncology, metabolism and cardiovascular diseases, immunology and respiratory diseases, as well as neuroscience, the company has continuously tackled drug development challenges. In order to conquer diseases, improve quality of life, and extend life, we are constantly pushing the boundaries of possibility, committed to using the power of science and technology to benefit patients worldwide.Known as the "Big Brother of Pharmaceuticals" in the industry for a long time.

Hengrui Pharma has Hengrui Medical under its umbrella,Founded inIn 2016,Focusing on the medical device track, as the carrier for the group's medical device industry development and capital operation, it bears the strategic mission of Hengrui Pharma’s expansion from the pharmaceutical industry to the healthcare industry. With an in-depth layout in high-value consumables fields such as oncology intervention, peripheral intervention, and neuro-intervention, it researches and develops medical devices including life support, imaging support, and interventional support, while proactively entering cutting-edge areas like drug delivery systems. It continuously strengthens its product pipeline and builds market advantages.

Not only are pharmaceutical companies entering the medical device track, but IVD companies in the industry are also expanding into pharmaceuticals. For example, Hotgen is developing innovative drugs and has established a presence in Sunjing; Baotai has been founded.Baotai Pharmaceuticals Enters the New Drug Field. The most successful company is Amoy Diagnostics, which focuses on companion diagnostics. It has reached companion diagnostic collaborations with many well-known pharmaceutical companies both in China and internationally, such as AstraZeneca, LOXO Lilly, Johnson & Johnson, Pfizer, Amgen, Merck, Eisai, Hengrui Pharma, and BeiGene. Amoy Diagnostics provides professional central laboratory testing and companion diagnostic registration services, supporting clinical research at various stages of drug development.

The trend of integrated development of pharmaceuticals and medical devices is becoming increasingly important in the strategic layout of medical enterprises.